BDTX Black Diamond Therapeutics, Inc.
USHealthcareAs of 2026-07-10 14:55
Why BDTX matters now
Black Diamond Therapeutics, Inc. (BDTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.88 with +0.05% on the session and $107.8M in market capitalization; recent performance reads 1-month -44.67% and YTD -31.69%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-9.0M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E 6.56 and FCF yield -35.8%.
The latest indexable market news headline is "Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Raman Prakash filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
6.56
PEG
0.05
P/B
0.91
P/S
0.00
EV/EBITDA
-2.18
DCF Value
$11.97
FCF Yield
-35.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.4%
ROA
-32.5%
ROIC
-43.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-9.0M | $-0.16 |
| Q4 2025 | $0.00 | $-15.1M | $-0.26 |
| FY 2025 | $70.0M | $22.4M | $0.39 |
| Q3 2025 | $0.00 | $-8.5M | $-0.15 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.23
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.